Terminated trial tests new hope for Tough-to-Treat breast cancer
NCT ID NCT06408168
Summary
This study aimed to see if a drug called repotrectinib, given with or without another drug called fulvestrant, could help control metastatic lobular breast cancer in people whose cancer had progressed after standard hormone-based treatments. It was a Phase 2 trial that enrolled only 6 participants before it was terminated. The main goal was to see if the treatment could keep the cancer from getting worse for at least 6 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.